Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
Status:
Not yet recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of selinexor combined with R-GDP regimen in the treatment
of patients with TP53-altered relapsed or refractory B-cell lymphoma.